Amylyx Pharmaceuticals, Inc. 8-K

What Happened

• On March 24, 2026 Amylyx Pharmaceuticals, Inc. (AMLX) filed a Form 8‑K (Regulation FD disclosure) to provide an updated corporate presentation for investor and analyst meetings. The presentation was revised to reflect the completion of enrollment in the Phase 3 LUCIDITY trial and other clinical trial updates. A copy of the presentation is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• The 8‑K was filed March 24, 2026 as a Regulation FD disclosure; the updated slides are provided as Exhibit 99.1.
• The presentation notes completion of enrollment in the Phase 3 LUCIDITY trial.
• It adds an exploratory analysis from the Phase 2 PREVENT study that was previously presented at the ENDO 2025 Annual Meeting.
• It also reports completion of enrollment for Cohort 2 in the Phase 1 LUMINA trial.

Why It Matters

• For investors, the filing confirms clinical development progress: Phase 3 LUCIDITY enrollment is complete, which may enable upcoming data readouts or regulatory milestones. The added PREVENT exploratory analysis and LUMINA Cohort 2 enrollment update give more context on Amylyx’s pipeline activity.
• This 8‑K is an informational update (Regulation FD) and does not report financial results, executive changes, mergers, or other corporate actions.